ReviewCurrent osteoporosis reports2026
A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.
Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThe purpose of this article is to emphasize the critical role aging and senescence plays on mesenchymal stem cell (MSC) functionality and its influence on bone health. This review also highlights recent advancements in strategies to rejuvenate senescent MSCs to aid in delaying or preventing age-related illnesses associated with bone loss. RECENT
findingsStudies have expanded upon many established rejuvenation strategies including senolytic agents, drugs used to selectively eliminate senescent cells, and targeted inhibitors to the secretory profile of senescent cells. New routes for MSC rejuvenation including nanoplatform targets such as biomaterials, nanovesicles, and physical exercise are showing promise for future clinical applications. Ongoing clinical trials are progressing towards rejuvenation therapies that delay age-induced bone loss. This review provides an overview of the current research landscape into rejuvenation of senescent MSCs to combat bone loss due to age and highlights new platforms and strategies for rejuvenation that could have clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.